Gerd Vanhaverbeke

436 total citations · 1 hit paper
15 papers, 255 citations indexed

About

Gerd Vanhaverbeke is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Gerd Vanhaverbeke has authored 15 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Genetics and 5 papers in Surgery. Recurrent topics in Gerd Vanhaverbeke's work include Diabetes Management and Research (13 papers), Diabetes and associated disorders (8 papers) and Diabetes Treatment and Management (4 papers). Gerd Vanhaverbeke is often cited by papers focused on Diabetes Management and Research (13 papers), Diabetes and associated disorders (8 papers) and Diabetes Treatment and Management (4 papers). Gerd Vanhaverbeke collaborates with scholars based in Belgium, Netherlands and United States. Gerd Vanhaverbeke's co-authors include Chantal Mathieu, Pieter Gillard, Frank Nobels, Bart Keymeulen, Chris Vercammen, Christophe De Block, Liesbeth Van Huffel, Sara Charleer, Steffen Fieuws and Toon Maes and has published in prestigious journals such as The Lancet, Diabetes Care and Diabetologia.

In The Last Decade

Gerd Vanhaverbeke

13 papers receiving 250 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial

2024 55 citations Katrien Benhalima, Dominique Ballaux et al. The Lancet Diabetes & Endocrinology profile →

Peers

Countries citing papers authored by Gerd Vanhaverbeke

Since Specialization

Citations

This map shows the geographic impact of Gerd Vanhaverbeke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerd Vanhaverbeke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerd Vanhaverbeke more than expected).

Fields of papers citing papers by Gerd Vanhaverbeke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerd Vanhaverbeke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerd Vanhaverbeke. The network helps show where Gerd Vanhaverbeke may publish in the future.

Co-authorship network of co-authors of Gerd Vanhaverbeke

This figure shows the co-authorship network connecting the top 25 collaborators of Gerd Vanhaverbeke. A scholar is included among the top collaborators of Gerd Vanhaverbeke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerd Vanhaverbeke. Gerd Vanhaverbeke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial 2025 ·EClinicalMedicine ·(unknown), (unknown), (unknown), Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, (unknown), Frank Nobels, Liesbeth Van Huffel, (unknown), Dahae Lee, (unknown), Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, Pieter Gillard, Chantal Mathieu, Jeroen Luyten, Katrien Benhalima	2
2	Who Benefits Most from Advanced Hybrid Closed Loop Therapy in Pregnancy Across Different Subgroups: A Secondary Analysis of the Randomized Controlled CRISTAL Trial 2025 ·Diabetes Technology & Therapeutics ·(unknown), (unknown), Marc Peeters, (unknown), Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, (unknown), Frank Nobels, Liesbeth Van Huffel, (unknown), Dahae Lee, (unknown), Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, (unknown), (unknown), Katrien Benhalima	0
3	One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study 2025 ·Diabetologia ·(unknown), Bart Keymeulen, Christophe De Block, Liesbeth Van Huffel, Youri Taes, Dominique Ballaux, (unknown), Bruno Lapauw, Gerd Vanhaverbeke, (unknown), Chris Vercammen, Ides M. Colin, Vanessa Preumont, Sara Charleer, Steffen Fieuws, Chantal Mathieu, Pieter Gillard	6
4	Diabetes mellitus geïnduceerd door immuuntherapie: een casus 2024 ·Tijdschrift voor Geneeskunde ·(unknown), (unknown), Gerd Vanhaverbeke, Sofie Derijcke, (unknown)	0
5	Cost–utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium 2024 ·Diabetologia ·(unknown), (unknown), Sara Charleer, John J. Isitt, Stéphane Roze, Christophe De Block, Toon Maes, Gerd Vanhaverbeke, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Jeroen Luyten, Pieter Gillard, Nick Verhaeghe	1
6	Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial breakdown → 2024 ·The Lancet Diabetes & Endocrinology ·Katrien Benhalima, (unknown), (unknown), Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, (unknown), Frank Nobels, (unknown), Dahae Lee, (unknown), Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, Pieter Gillard, Chantal Mathieu	55
7	Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial 2024 ·Diabetes Care ·(unknown), Pieter Gillard, (unknown), Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, (unknown), Frank Nobels, Liesbeth Van Huffel, (unknown), Da Young Lee, (unknown), Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, Chantal Mathieu, Katrien Benhalima	12
8	Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial 2023 ·The Lancet Diabetes & Endocrinology ·(unknown), Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, (unknown), Chris Vercammen, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Pieter Gillard	27
9	Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial – study protocol 2023 ·BMC Pregnancy and Childbirth ·(unknown), (unknown), Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, (unknown), Frank Nobels, (unknown), Da Young Lee, (unknown), Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, Pieter Gillard, Chantal Mathieu, Katrien Benhalima	19
10	The Impact of Baseline User Characteristics on the Benefits of Real-Time Versus Intermittently Scanned Continuous Glucose Monitoring in Adults With Type 1 Diabetes: Moderator Analyses of the ALERTT1 Trial 2022 ·Journal of Diabetes Science and Technology ·(unknown), Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, (unknown), Chris Vercammen, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Pieter Gillard	5
11	Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial 2021 ·The Lancet ·(unknown), Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, (unknown), Chris Vercammen, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Pieter Gillard	107
12	Lipohypertrophy Monitoring Study (LIMO): Effect of single use of 4 mm pen needles combined with education on injection site rotation on glycaemic control: Confirmation of an unpleasant truth 2021 ·Diabetic Medicine ·(unknown), Katelijn Decochez, (unknown), (unknown), Chris Vercammen, Peter Coremans, Gerd Vanhaverbeke, Samyah Shadid, Bart Keymeulen, (unknown), Christophe De Block	14
13	Lipohypertrophy monitoring study (LIMO): effect of injection site rotation and education on glycemic control 2021 ·Endocrine Abstracts ·(unknown), Katelijn Decochez, (unknown), (unknown), Chris Vercammen, Peter Coremans, Gerd Vanhaverbeke, Samyah Shadid, Bart Keymeulen, (unknown), (unknown)	1
14	DIABETIC MANAGEMENT IN HIGH RISK PATIENTS (PREGNANCY, INSULIN PUMPS) 2004 ·Acta Clinica Belgica ·Gerd Vanhaverbeke, Ann Mertens, Chantal Mathieu	3
15	Follicular Carcinoma of the Thyroid with Poorly Differentiated Component Presenting with an Ileal Osteoblastic Metastasis 2004 ·Thyroid ·Gerd Vanhaverbeke	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact